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Background: Refractory angina is a severe chronic disease, defined as angina which cannot be controlled by usual
treatments for heart disease. This disease is frightening, debilitating, and difficult to manage. Many people suffering
refractory have inadequate pain relief, continually revisit emergency departments for help, undergo repeated
cardiac investigations, and struggle with obtaining appropriate care. There is no clear framework to help people
understand the risks and benefits of available treatment options in Canada. Some treatments for refractory angina
are invasive, while others are not covered by provincial health insurance plans. Effective care for refractory angina
sufferers in Canada is critically underdeveloped; it is important that healthcare professionals and refractory angina
sufferers alike understand the treatment options and their implications. This proposal builds on the recent Canadian
practice guidelines for the management of refractory angina. We propose to develop a decision support tool in
order to help people suffering from refractory angina make well-informed decisions about their healthcare and
reduce their uncertainty about treatment options.
Methods: This project will be conducted in three phases: a) development of the support tool with input from
clinical experts, the Canadian refractory angina guidelines, and people living with refractory angina, b) pilot testing
of the usability of the tool, and c) formal preliminary evaluation of the effectiveness of the support tool to help
people make informed decisions about treatment options.
Discussion: A decision support tool for refractory angina is needed and the available data suggest that by
developing such a tool, we may be able to help refractory angina sufferers better understand their condition and
the effectiveness of available treatment options (in their respective clinical settings) as well as their implications (e.g.
risks vs. benefits). By virtue of this tool, we may also be able to facilitate identification and inclusion of patients’
values and preferences in the decision making process. This is particularly important as refractory angina is an
intractable condition, necessitating that the selected course of treatment be lifelong. This study will yield a much
needed patient decision aid for people living with refractory angina and pilot data to support a subsequent
effectiveness study.
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Refractory angina (RFA) is a debilitating chronic disease,
resistant to conventional treatments for coronary artery
disease (CAD) including nitrates, calcium-channel and β
adrenoceptor blockade, vasculoprotective agents, per-
cutaneous coronary interventions, and coronary artery
bypass grafting [1,2]. Reasons for this habituation may
include coronary anatomy that precludes effective re-
peat revascularizations, and extra-cardiac diseases that
potentiate peri-operative morbidity (e.g. carotid sten-
osis, renal insufficiency) [2]. When untreated, repeated/
chronic myocardial ischemia, inherent in RFA, can lead
to maladaptive anaerobic glycolysis, tissue lactate produc-
tion, accumulation of catabolites, and potassium efflux
into the extracellular space [3,4]. Intrinsic compensatory
mechanisms to correct these imbalances (e.g. myocardial
hibernation, stunning) often fail, resulting in severe myo-
cardial cellular dysfunction or death [3-5].
As more patients survive primary and subsequent car-
diac events, the global prevalence of RFA is rising [2].
Estimates suggest that RFA affects between 600,000 and
1.8 million people in the United States [6] and that there
are 30–50,000 new cases per year in continental Europe
[2,6,7]. Canadian Community Health Survey data suggest
that approximately 500,000 Canadians live with unre-
solved angina [8]. The annual mortality rate of patients
living with RFA is not known but is thought to be in the
range of approximately 3% [9]. Those living with RFA suf-
fer severely impaired health-related quality of life (HRQL)
including recurrent and sustained cardiac pain, psycho-
logical distress, impaired role functioning, activity restric-
tion, and inability to self-manage [10,11].
In Canada, those with RFA struggle to obtain appropriate
care. Some treatments for RFA are invasive, while others
are not covered by provincial health insurance plans.
Moreover, the effectiveness of these treatments varies by
outcome [2,5]. To date, there is no clear, comprehensive
patient decision making framework to help people under-
stand the available treatment options and their relative
risks and benefits.
Patient decision aids
According to the International Patient Decision Aids
Standard (IPDAS) collaboration [12,13] patient decision
aids (PtDAs) are evidence-based tools designed to help
people engage in deliberative treatment-related decision
making by providing information on the options and
outcomes relevant to health status. These tools are used
to supplement, not replace, consultation between health
care professionals (HCP) and patients [12,13]. In so
doing, PtDAs help individuals to understand the range
of options available and the probable consequences of
various treatment options [12,13]. When designed opti-
mally, PtDAs also distill for patients they value theyplace on the potential consequences of treatment ap-
proaches (e.g. invasive, non-invasive).
A recent (2011) Cochrane review of 86 studies [14]
found that relative to routine health professional coun-
seling, PtDAs improve patients’ knowledge of treatment
options and perception of outcome probabilities, as well
as their level of involvement in shared decision making.
Ideally, effective PtDAs express outcome probabilities in
both visual and written form to communicate absolute
risk or benefit clearly to patients (i.e., X people out of
100) [15]. There is general consensus that decision sup-
port tools do not include passive informed consent ma-
terials, educational interventions not geared to a specific
decision, or interventions designed to promote compli-
ance with a recommended option rather than a choice
on personal values [16,17]. Decision support tools have
been developed in a range of formats including deci-
sion boards, interactive videodiscs, personal computers,
audio-tapes, audio-guided workbooks, pamphlets, and
group presentations [14].
Study aims
The aims of this study are to:
1. Develop a decision support tool to promote and
support informed RFA patient-health care professional
decision making about available treatment options,
and
2. Conduct preliminary testing of this tool.
Driven by the IPDAS quality framework [18] the specific
aims of the PtDA are to:
1. Improve patients’ understanding of RFA, including
the natural history of the condition if no action is
taken,
2. Increase knowledge about the probable and relative
effectiveness of available treatment options, as well
as their potential risks and benefits, to solicit
patients’ values and preferences about these
treatment options, and to reduce RFA-treatment-
related decisional conflict.
Conceptual framework
The overarching conceptual framework giving direction to
this project is the Ottawa Decision Support Framework
[15]. Derived from concepts across general and social
psychology, decision analysis, decision conflict, values,
and social support and self-efficacy [19-25], this frame-
work is an evidence-based, transdisciplinary, conceptual
framework that can be used to guide the decision making
process in clinical practice. The framework was developed
for health decisions that a) are stimulated by a new cir-
cumstance, diagnosis, or developmental transition, b)
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and/or value-sensitive nature of the benefits and risks,
and/or c) need relatively more effort during the deliber-
ation phase than the implementation phase. The frame-
work consists of three elements, including: assessment
of needs or determinants of decisions, provision of deci-
sion support, and evaluation of the decision making
process and outcomes of decisions made [15]. Evalu-
ation of the quality of decision making is separated, con-
ceptually, from the outcomes of care-related decisions
themselves [15].
Hypotheses derived from the Ottawa Decision Support
Framework [15], which have guided examination of the
effects of decision support interventions, have been em-
pirically tested. Decision support interventions, which
include information, values clarification, and guidance in
deliberation, have consistently produced hypothesized im-
provements in knowledge, treatment and outcome expec-
tations, and decisional conflict in pre/post studies [26-30]
as well as RCTs [14,31]. The available evidence, testing the
propositions of the Ottawa Framework, appears to be con-
sistent with the findings of the recent Cochrane review
[14] on the overall effectiveness of decision support tools.
On this basis, we concluded that the Ottawa Framework
is a sound, theory-driven, and empirically supported con-
ceptual framework to guide our development and prelim-
inary evaluation of a PtDA for RFA.
Methods
To meet the research objectives, this project involves an
overall three-phase PtDA development and pilot testing
methodology (see Figure 1), adapted from previous, vali-
dated work [32]. The first phase, now underway, in-
cludes the development of the decision support tool and
review by expert practitioners, and our key stakeholderFigure 1 Study flow diagram. PtDA patient decision aid; RFA refractory anginterest groups including decision scientists, patient ad-
vocacy representatives, policy makers, and patients living
with RFA. The second phase will involve pilot testing
with a convenience sample, representative of people liv-
ing with RFA from across Canada. The third phase will
involve a local pretest-posttest evaluation of the decision
support tool for people newly diagnosed with RFA. This
study protocol was approved by the Hamilton Integrated
Research Ethics Board (protocol reference [ref] #13-847),
the University of Toronto Research Ethics Board (proto-
col ref #28970), the University Health Network Research
Ethics Board (protocol ref #13-6667-AE), the Providence
Health Care Research Ethics Board (protocol ref #H13-
01094), and the Royal Jubilee Hospital Clinical Research
Ethics Board (protocol re #C2014-022).
Phase I: Development of the decision support tool
The steering committee overseeing this study is com-
prised of the investigative team, RFA patient repre-
sentatives, our non-governmental organization decision
making partners, clinician stakeholder representatives,
and a web designer. This committee oversees all aspects
of development and evaluation of the decision support
tool. Driven by the Ottawa Decision Support Framework
[15], the information, content, and format of the PtDA
were developed via a) systematic review of the available
evidence, b) steering committee input, c) evaluation of
needs assessments of individuals with RFA, and d) input
from all key informants, as follows:
Systematic review of the available evidence and
data extraction
Multiple intervention approaches for RFA have been de-
veloped and tested (to varying degrees of rigour) in
North America and continental Europe over the last twoina.
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external counter-pulsation, temporary cardiac sympath-
ectomy, laser revascularization, high thoracic epidural
anesthesia, heart rate modulating and metabolic agents,
opioids, shock wave therapy, myocardial cryotherapy,
coronary sinus reducer, stem cell therapy, and cognitive-
behavioural interventions [5]. Prior to submission of this
protocol for research ethics board (REB) approval, our in-
vestigative team developed and published the Joint Canad-
ian Cardiovascular Society-Canadian Pain Society clinical
practice guidelines (CPGs) for the management of RFA [5].
These CPGs featured a large-scale systematic review and
meta-analysis of all above-listed treatment options for RFA;
the evidence base included systematic reviews, randomized
controlled trials (RCT), quasi-experimental studies, and
pre-post observational designs. All studies were evaluated
for methodological rigor using the Grading Recommenda-
tions, Assessment, Development and Evaluation (GRADE)
system of evidence evaluation. Based on the IPDAS 2006
Checklist for Judging the Quality of Patient Decision Aids
[33], we developed a data extraction form in order for
the Research coordinator (RC) to extract the informa-
tion needed on each treatment option for the PtDA (e.g.
availability, safety, modes of action, logistical consider-
ations, cost implications, and potential risks/benefits).
Needs assessment
We have published and are aware of several publications
on the information and decision-related needs of people
with RFA [10,11,34-36]. The RC abstracted relevant data
from these publications including a) the natural course
of RFA, b) patients’ experiences of various treatment op-
tions (e.g. life implications, side effects), c) degree of diffi-
culty in making treatment-related choices, and d) attitudes
about decision support.
Input from key informants
Input from key informants was obtained via a full-day,
investigator-decision maker-collaborator consensus mee-
ting in order to come to consensus on decision tool
content and format. Our process was governed by an
inductive consensus procedure entitled Technique for
Research of Information by Animation of a Group of
Experts (TRIAGE) [37]. Rooted in the constructivist
paradigm of social research, the TRIAGE procedure dif-
fers from the Delphi Technique [38] and the Nominal
Group Technique [38] in that exchange of ideas is not
exclusively via control of a group leader or survey
medium. Three formal steps are involved: 1) preparation,
2) individual production, and 3) interactive production
[37]. Preparation: Our key informants included those
directly involved in the governance of this research pro-
ject as well as the primary authorship panel of the Joint
RFA guidelines [5]. The RC mailed each participant apackage containing a) a briefing document on our collect-
ive purpose, b) the Ottawa Decision Making Framework
[15] and IPDAS quality checklist [33], c) the specific aims
of the decision support tool, and d) a consensus confer-
ence worksheet. They were also sent an abridged version
of the Joint RFA guidelines [5], highlighting the data on
the effectiveness of the available treatment options, as well
as outcome probabilities. Participants were asked to re-
view these materials in advance of the conference. Individ-
ual production: Participants were asked to document up
to 5 priorities for the PtDA on their worksheets, in light of
the materials they reviewed. They then sent their work-
sheets back to the RC by mail or portable document for-
mat (PDF) via email. Prior to the consensus meeting,
these priorities were categorized into the key ‘indicators’
or stems for discussion/debate. Interactive production:
This final step involved the consensus conference itself.
According to TRIAGE [37] a pre-established agenda is re-
quired as well as a facilitator who is competent in group
dynamics management. An appointed facilitator guided
the discussion to generate consensus on specific content
around each ‘indicator’ (identified in Step 2). The mechan-
ics of this process relied on a prominent visual aid,
whereby ideas were documented as collectively ‘accepted’,
‘vetoed’, or ‘held’ for future consideration [37].
Creation of the draft decision aid
Information garnered from all preceding stages of Phase
1 was incorporated into the draft PtDA. The construc-
tion of the draft PtDA was based on the following com-
ponents, according to the IPDAS quality checklist [33]
framework and the guiding principles of the Ottawa De-
cision Framework [15], as follows:
A) Information about options and outcomes The PtDA
includes a description of the clinical situation (i.e., a diagno-
sis of RFA) that has stimulated the need to consider certain
options and outcomes. Each treatment viable option was
described in detail. The potential outcomes of each option
were also described so that end-users will be able to under-
stand what it may be like to experience each outcome. The
functional impact of each outcome was also described (e.g.
how the person can expect to respond to each treatment
physically, emotionally, and socially) [15,18].
B) Presentation of probability of outcomes One of the
consistent benefits of PtDAs is to create realistic expecta-
tions of outcomes [14]. This was achieved by presenting
probabilistic information about the likelihood of desirable
and undesirable effects of all treatment options [15,18].
C) Values clarification the PtDA was designed to ask
participants to consider explicitly the personal import-
ance of potential benefits and harms associated with
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cise was to structure and provide insight into how values
affect personal decision making about options and to
communicate those values [15,18]. This exercise was
presented in the form of a ‘weigh scale’, wherein partici-
pants are presented with the potential desirable/undesir-
able effects of each option. They are then prompted to
add any additional positive or negative factors which are
important to them, check or shade each of these items
in the ‘weigh scale’ to indicate their relative importance,
and then indicate their predisposition toward one avail-
able treatment option versus others.
D) Coaching or Guidance Guidance and coaching have
been found to be helpful in promoting better coping
strategies, health practices, and outcomes [14]. Structure
and guidance in decision making was provided in the
PtDA by illustrating the decision making process, in-
cluding considering personal benefits and risks, b) clari-
fying level of certainty, knowledge and personal values,
c) listing of current health practices, d) listing questions,
e) indicating preferred role in decision making, and e)
indicating current predisposition toward options. The
general Ottawa Personal Decision Guide will was used
to develop this illustrative process [39].
E) Delivery For the purpose of this research study, the
format of the PtDA for participants will be a paper-
based version (see Phases 2 and 3). For our internal de-
velopment and revision purposes, an electronic version
of the tool has been housed on a secure, password-
protected section of the website of one of our non-
governmental organization partners.
Review and revisions to draft decision aid
The draft PtDA will be reviewed and critiqued by all
stakeholders who were involved in our consensus con-
ference proceedings, plus external RFA content experts.
For the purposes of this review, we have created a se-
cure, password-protected and interactive online environ-
ment entitled Decision Aid Manager. All reviewers will
be asked to logon to Decision Aid Manager in order to
view a PDF of the PtDA and assess its content using a
quality assessment tool we adapted from the IPDAS
quality checklist [33]. This exercise will include rigor of
development as well as the effectiveness of the PtDA to
help patients a) recognize that a decision needs to be
made, b) know the available treatment options, as well
as their features and potential risks and benefits (in
equal detail), c) understand their values and preferences
that affect decision making, and d) become involved in
decision making in preferred ways. Decision Aid Man-
ager includes both a ‘yes/no’ checklist for content-related
items and a 5-point Likert scale for effectiveness-relateditems, ranging from 0 = ‘not effective at all’ to 4 = ‘very
much effective’. This scale was adapted, with permission,
from the effectiveness subscale of Sidani et al.’s Treat-
ment Acceptability and Preference Questionnaire (TAP)
[40]. The TAP has established internal consistency and
validity, demonstrated by a 1-factor structure and signifi-
cant differences in scores between patients with differing
treatment preferences [40]. We will use our scale to as-
sess areas of strengths and weaknesses of the PtDA;
items rated as 2/4 (i.e. effective) or lower will indicate
areas requiring attention. Our Decision Aid Manager
also includes an open comment box to facilitate feed-
back on the overall presentation of the tool including
clarity, user-friendliness, and visual appeal. Descriptive
statistics will be computed by the biostatistician on our
team and the RC will use the quantitative and qualitative
data derived to create a feedback report of the findings
of this review. As a form of integrated knowledge trans-
lation (KT), this report will be made available online to
all reviewers via Decision Aid Manager, which also fea-
tures a web-based discussion forum. We will host a
week-long asynchronous discussion forum, calling for a
collective ‘brainstorming’ session on how the PtDA
should be revised, based on our feedback report. This
study phase (i.e. review and feedback) will be carried out
via a mail out and telephone-based feedback process for
those who prefer paper-based media, or do not have
convenient access to a computer.
Phase 2: Pilot test 1
The purpose of Pilot 1 is to ensure that the PtDA is a)
clearly formatted, b) acceptable to patients, and c) feas-
ible for patients to complete (i.e. completion is with ease
and time-efficient).
Sample and setting
Pilot 1 will involve a convenience sample of 40 RFA pa-
tients from across Canada. Those eligible will include
patients who a) have a confirmed diagnosis of RFA [5],
b) are currently being treated, and c) are able to read,
speak and understand English. We are including experi-
enced patients in this phase of the study because the ef-
fectiveness of the tool for supporting ‘good decisions’
cannot be presumed until accessibility is assessed; those
newly diagnosed could be unduly influenced by a poten-
tially unacceptable tool. This convenience sample will be
recruited from 8 cardiac centres across Canada, with
established cohorts of RFA patients undergoing active
treatment.
Regional variations in RFA care exist across Canada
with respect to availability of treatment options, requis-
ite clinical skills, and insurance coverage [1]. Inherent in
the notion of acceptability is relevance to our end-users.
Hence, acceptability assessment by patients from across
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based on a review by Hertzog [41], suggesting a range of
20–40 participants to allow for sufficient variability in
acceptability assessment of an intervention. Our accept-
ability data will be used to revise the PtDA, which will
be tested as an intervention in a subsequent randomized
controlled trial.
Procedure
The research process will be governed centrally. Each
clinical site has a running list of known RFA patients.
Designated third-party clinicians at each site will ask eli-
gible patients if they would be willing to speak to the RC
about the study. If verbal consent is obtained, contact
information will be sent to the RC via telephone (to pre-
serve confidentiality). The RC will then phone the re-
ferred individual to confirm eligibility, provide a detailed
study explanation, and obtain preliminary verbal con-
sent. Eligible patients agreeing to participate will be
asked for baseline demographic information via phone
interview. They will receive the study explanation, two
copies of the consent form, and the draft decision sup-
port tool in the mail; a postage-paid, addressed envelope
will be included to return one signed consent form to
the RC. Participants will be asked to take 1–2 weeks to
review the PtDA. The RC will schedule a follow-up
phone call wherein participants will be asked to com-
plete a PtDA Acceptability Questionnaire via phone
interview; this process will take approximately 10–15
minutes. The RC will collate the data from this accept-
ability pilot and appropriate revisions will be made to
the PtDA. A maximum of 5 participants per site is re-
quired. Based on up-front consultation with our clinical
sites, we foresee no difficulty in obtaining the required
sample.
Phase 3: Pilot test 2 (pretest-posttest evaluation)
The overall aim of Pilot 2 is to field test the PtDA in the
clinical setting. While the Cochrane review [14] of
PtDAs demonstrated the general effectiveness of such
tools for a) improving patients’ knowledge of the prob-
able outcomes of various treatment options, b) changing
patients initial treatment decisions/inclinations once
relative risks were accurately perceived, and c) improving
patients’ comfort and level of involvement with decision
making, several questions remain. Clinical contextual fac-
tors may impact the effectiveness of a PtDA and will be
taken into account, including the willingness of health
care providers (HCPs) to use these tools, HCPs’ level of
skill in shared decision making, and effectiveness of sys-
tems for decision support implementation. Operating in
concert with such factors are the individual values and
preferences which patients, and HCPs alike, bring to the
clinical encounter. The degree to which these values andpreferences are congruent with chosen treatment options
varies [14]. Understanding these factors requires not only
examination of PtDA effectiveness, but also the context of
implementation and HCP-patient interactions during this
process. We will therefore employ a combination of sum-
mative and formative research methods in Pilot 2.
While the Ottawa Decision Support Framework [15]
guides our overall process for designing and testing the
decision support tool, our conceptualization of Pilot-2 is
also guided by the Ottawa Model of Research Use
(OMRU) [42]; there are several elements of the OMRU
that are conceptually consistent with the Ottawa Deci-
sion Support Framework. OMRU is an interactive model
designed for the evaluation of KT innovation imple-
mentation. Within the OMRU [42] there are six key
elements that interface to determine the process of
knowledge translation: 1) evidence-based innovation,
2) potential adopters, 3) the practice environment,
4) implementation of interventions, 5) adoption of the
innovation, and 6) outcomes of innovation implementa-
tion. In the context of Pilot-2, the innovation is the
PtDA, the potential adopters are our participating HCPs
and RFA patients, and the practice environment will
constitute our Pilot 2 settings.
Primary purpose
The primary purpose is to determine the appropriate-
ness and acceptability of the PtDA for our key effective-
ness outcomes including decisional conflict (primary
outcome) and knowledge of treatment options, and
choice predisposition (secondary outcomes). This pilot
test will allow us to determine the effect size of the
PtDA, which will inform the required sample size for a
randomized controlled trial (RCT) of the effectiveness of
the tool as an intervention.
Secondary purpose
The secondary purpose is to a conduct a formative
evaluation of the use of PtDA while in use. This evalu-
ation will allow us to conduct a preliminary assessment
of predisposing, enabling, and reinforcing factors [42]
which may impact the ability of the tool to effectively
translate knowledge about various treatment options,
and support informed decision making, within the clin-
ical context.
Sample and setting
Pilot 2 will involve a convenience sample of 20 RFA pa-
tients from two, large urban cardiac centres in Southern
Ontario, Canada. Two centres will be used to allow for
examination of differences in contextual factors that
may impact the effectiveness of the PtDA. Those eligible
will include patients who a) are diagnosed with RFA
[15], b) require, and have not yet undergone, a specific
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speak with a site-designated HCP about treatment options
within the study period, and d) are able to read, speak,
and understand English. This sample size was chosen
based on Hertzog’s recommendation [41] of a minimum
of 20 participants for single sample pre-post pilot studies
used to develop both estimates of effect size and variance
for a RCT. larger trial. In addition, based on Cochrane
data [14], we anticipate that for a level of significance of
alpha = 0.05, power (1-beta) = 0.80, a standard deviation of
0.81, and a correlation between pretest and posttest scores
of 0.80, we will be able to detect a difference of 0.34 in de-
cisional conflict scores (range: 1–5). This represents a
moderate effect size [43], which is typical of PtDAs [14]
and also clinically meaningful given that it is has been ob-
served between those who make decisions versus those
who delay decisions [44].
As guided by OMRU [42], our implementation, struc-
tured adoption (for the purposes of pilot testing), and
outcome evaluation will be as follows:
Field test procedure and outcomes
As an integrated KT strategy involving stakeholders from
the inception of this project, Pilot 2 site co-investigators
and collaborators are assisting us to establish site-
designated HCPs, who will assist us with recruitment.
These HCPs will be oriented to the study and proce-
dures for pilot testing the PtDA during scheduled visits
with their patients enrolled in the study. Potentially eli-
gible patients, identified by these HCPs, will be asked if
they would be willing to speak to the RC about the
study. If verbal consent is obtained, contact information
will be sent to the RC via telephone. The RC will then
phone the referred individual to confirm eligibility, pro-
vide a detailed study explanation, and obtain preliminary
verbal consent. Eligible patients agreeing to participate
will be asked for baseline demographic information via
phone interview. They will receive the study explanation,
and two copies of the consent form; a postage-paid, ad-
dressed envelope will be included to return one signed
consent form to the RC. Approximately 1 month prior
to their scheduled visits with a site-designated HCP, the
RC will conduct pre-test data collection via telephone
interview, using our pre/post-test questionnaires. These
instruments are designed to assess knowledge about
treatment options, decisional conflict, and predisposition
about treatment options. Upon completion of baseline
data collection, the RC will mail participants a copy of
the decision support tool. Participants will be asked to
review the decision support tool and arrangements will
be made for them to complete the PtDA Acceptability
Questionnaire via telephone with the RC.
A paper-based version of the decision support tool will
be implemented during participants’ scheduled visitswith their site-designated HCPs. Where permission is
granted (by participants and site-HCPs), the RC will
make arrangements for these sessions to be audio-taped
and later, transcribed verbatim. While discussing/delib-
erating treatment options, participants will be encour-
aged to share their thoughts on the decision support
tool, ask questions about the available RFA treatment
options, and discuss any concerns that they may have.
This iterative approach supports the interactive princi-
ples of integrated knowledge translation [45-47]. One
week following these scheduled visits, the RC will con-
duct post-test outcome assessment via telephone inter-
views, using our pre/post-test questionnaires.
Post-field test debriefing interviews
Once post-test measures are completed, the RC will con-
duct a brief, semi-structured follow up debriefing inter-
view with each participant, focusing on the experience
of using the decision support tool; this will also be con-
ducted via telephone. These interviews will be con-
ducted according to a semi-structured patient interview
guide we have developed based on the OMRU know-
ledge translation framework. This guide will solicit parti-
cipants’views about the impact of their values on
decsions made, changes that may have occurred in
treatment-related preferences and perceptions of risks/
benefits, general reflections on the decision making
process, applicability and usefulness of the decision sup-
port tool in context (e.g. barriers, facilitators to use), and
their level of comfort interacting with the HCPs when
using the tool. For efficiency of data collection, the RC
will conduct a similar debriefing with our site HCPs in
the form of focus groups; one focus group per site will
be conducted. A semi-structured HCP focus group inter-
view guide will also be used, also based on OMRU.
These discussion questions will target HCPs’ views of
the applicability and utility of the decsion support tool
in their respective practice contexts, perceived efficacy
of the tool in assisting their patients to arive at
treatment-related decions, and perceived enablers and
facilitators to decision tool implementation. The RC will
take field notes, and these sesions will be audio-taped
and transcribed verbatim, in preparation for qualitative
content analyses.
Instrumentation: pre/posttest measures
Acceptability questionnaire Decision support tool ac-
ceptability will be assessed using the Decision Aid Ac-
ceptability Questionnaire [32], comprised of open and
closed-ended questions. Closed-ended questions will
elicit feedback on amount of content, clarity, and help-
fulness of the PtDA, acceptability of format, whether the
information was presented in a balanced and fair
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mend it to other RFA patients. Evidence supports the valid-
ity of the Decision Aid Acceptability Questionnaire [32].
Decisional conflict scale The Decisional Conflict Scale
(DCS) [48] will be used to measure the primary effect-
iveness outcome of decisional conflict [49,50]. The pur-
pose of this scale is to measure a person’s perception of
difficulty in making a decision including, perceived un-
certainty in choosing between options; modifiable factors
contributing to uncertainty such as feeling uninformed,
unclear about personal values, and unsupported; and
quality of the choice selected. Choice quality is defined
as choice that is informed, consistent with personal
values, and personally satisfying satisfaction [32,48]. The
DCS consists of 16 items. Scoring involves the summa-
tion and averaging of the items, ranging from 1 (low de-
cisional conflict) to 5 (high decisional conflict). Scores of
2.0 or lower are associated with those who make deci-
sions; scores of 2.5 or greater are associated with those
who delay decisions [48]. The DCS has been used to as-
sess health-related decisions across divergent health con-
ditions and contexts [32,48]. Test-retest and internal
consistency coefficients exceed 0.78. This scale varies in
its ability to discriminate between different decision-
supporting interventions [32,48].
Knowledge/comprehension test Knowledge of RFA
treatment options will be assessed using a knowledge
questionnaire developed for this study. We will use a
standardized, validated format developed by Metcalfe
et al. [32] that includes items regarding the mechanisms
of action and effectiveness of various (RFA) treatment
options, as well as known possible adverse effects. Ef-
fectiveness estimates will be presented in the form of a
continuous scale from 0 to 100%. Content knowledge
items will be presented as ‘true’ or false’; these items will
be developed as part of our consensus conference.
Choice predisposition tool Participants’ decision pre-
dispositions will be measured using the Choice Predis-
position Tool [15,32]. Participants will be asked to mark
along a 15-point scale anchored by ‘not leaning towards’
or ‘leaning towards’ particular treatment options (e.g.
Spinal cord stimulation, enhanced external counter-
pulsation); a response option in the middle indicates ‘un-
sure’. Test-retest reliabilities of various iterations of this
scale, across populations, exceed 0.90; they are also con-
sistently correlated with personal values and expecta-
tions, and sensitive to change [15,32].
Data management and analyses
All electronic and audio-taped data will be secured in a
locked facility. To inform sample size calculations anddata analysis feasibility for a larger trial, data will be ana-
lyzed as in a larger study, and estimates of variance and
correlation (i.e. intracluster correlation within site) will be
generated. All quantitative data collected will be checked
for departures from normality and analyzed initially with
descriptive statistics; measures of central tendency and
dispersion (e.g. means and standard deviations) will be
computed for continuous variables. For categorical demo-
graphic variables, frequencies and proportions will be re-
ported. Differences between pre and post-intervention
measures will be examined using paired t-tests for all
interval scaled measures, provided the assumption of nor-
mality is met [51]. Where the normality assumption is vio-
lated, the non-parametric Wilcoxon signed-rank test will
be used [51].
As this protocol focuses on appropriateness, accept-
ability and pilot testing of the PtDA, no sub-analyses
were planned to examine the influence of participant
characteristics such as age, sex, and highest level of for-
mal education on the outcomes of decisional conflict,
knowledge of treatment items, and choice predispos-
ition. Examination of the influence of participant charac-
teristics will be undertaken in a subsequent effectiveness
RCT.
An examination of missing data will be of particular
importance to the pilot analysis. The level and pattern of
missing data will be quantified. Presence versus absence
of data for each scale will be compared across demo-
graphic and clinical characteristics to identify particular
groups of individuals that may have a higher propensity
for missing data.
All transcribed qualitative data, including needs assess-
ment data, HCP-participant visits, participant follow-up
interviews, and HCP focus groups will be analyzed using
inductive thematic qualitative content analysis [52-54].
The frequency, extensiveness, and specificity of com-
ments will guide data categorization into recurrent
themes [52-54]. These themes will be altered and refined
through a recursive process from the data to analyst-
generated categorical and conceptual definitions.
Discussion
This paper describes the protocol for the development
and pilot testing of a PtDA for those who suffer RFA. A
number of RCTs to date have examined the effectiveness
of PtDAs in specific cardiac populations such as ische-
mic heart disease [55], newly diagnosed hypertension
[56] and/or dyslipidemia [57], atrial fibrillation [58], and
those referred for diagnostic coronary angiography [59].
The results of these primary trials corroborate with
those of the 2011 Cochrane review [14]. Consistent im-
provements were found in patients’ knowledge of their
conditions and available treatment options [56-59], deci-
sional conflict and perceptions of potential outcome
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patient autonomy in the shared decision making process
[55]. One RCT also found that engagement with a PtDA
did not increase participants’ state anxiety [56], suggest-
ing that informing cardiac patients about potential treat-
ment risks, and addressing their preferences does not
impose added psychological burden. In a RCT of a PtDA
to augment pharmacist consultation about lipid lowering
and/or antihypertensive pharmacotherapies, no impact
on patients’ knowledge or risk perception was found
[57]. However, clinician-patient interactions with the de-
cision tool were brief and the complexity of the tool may
have been a contributing factor [57].
While a PtDA has been designed specifically for an-
gina [60] this tool targets therapies for chronic stable an-
gina and unstable angina, two conditions which, unlike
RFA, are amenable to standard medical therapies. More-
over, we found that this tool did not meet the internal
quality and impact standards set forth by the IPDAS
[18], receiving scores of 5/9 and 0/2 for development
process and effectiveness criteria, respectively [33].
A decision support tool for RFA is needed and the
available data suggest that by developing such a tool, we
may be able to help RFA sufferers better understand
their condition and the effectiveness of available treat-
ment options (in their respective clinical settings) as well
as their implications (e.g. risks vs. benefits). By virtue of
this tool, we may also be able to facilitate identification
and inclusion of patients’ values and preferences in the
decision making process. This is particularly important
as RFA is an intractable condition, necessitating that the
selected course of treatment be lifelong [1,2,5,6].
This study will yield a much needed PtDA for people
living with RFA and pilot data to support a subsequent
effectiveness study.
Study status
Phase 1 is complete and participants are currently being
enrolled in Pilot 1.
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